A case of intestinal Behçet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years

Yuriko Maruyama, Tadakazu Hisamatsu, Katsuyoshi Matsuoka, Makoto Naganuma, Nagamu Inoue, Haruhiko Ogata, Yasushi Iwao, Takanori Kanai, Toshifumi Hibi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Behçet's disease is a chronic relapsing disease with multiple organ system involvement, including the gastrointestinal tract, which is known as intestinal Behçet's disease. Intestinal Behçet's disease is often resistant to empirical treatments such as 5-aminosalicylic acid, immunomodulators and steroids and often causes a perforation, requiring surgical resection. Therefore, intestinal lesions are considered to be a poor prognostic factor in Behçet's disease. Recently, several reports have demonstrated the efficacy of anti-TNFα monoclonal antibodies, such as infliximab, against intestinal Behçet's disease, however, it remains unknown whether anti- TNFα therapy can improve the prognosis of patients with intestinal Behçet's disease. We herein report the case of an adult female patient with intestinal Behçet's disease who responded well to the induction therapy with infliximab, and has been maintained in remission by scheduled administration of infliximab. Her C- reactive protein level has been sustained at a negative level, and endoscopic findings revealed complete mucosal healing. Therefore, infliximab may have the potential to induce "sustained deep remission" in patients with intestinal Behçet's disease.

Original languageEnglish
Pages (from-to)2125-2129
Number of pages5
JournalInternal Medicine
Volume51
Issue number16
DOIs
Publication statusPublished - 2012

Fingerprint

Intestinal Diseases
Mesalamine
Immunologic Factors
C-Reactive Protein
Gastrointestinal Tract
Infliximab
Chronic Disease
Therapeutics
Steroids
Monoclonal Antibodies

Keywords

  • Infliximab
  • Intestinal Behçet's disease
  • Mucosal healing
  • Sustained deep remission

ASJC Scopus subject areas

  • Internal Medicine

Cite this

@article{1cb8d6528fbd4716842b501ed0be4b6e,
title = "A case of intestinal Beh{\cc}et's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years",
abstract = "Beh{\cc}et's disease is a chronic relapsing disease with multiple organ system involvement, including the gastrointestinal tract, which is known as intestinal Beh{\cc}et's disease. Intestinal Beh{\cc}et's disease is often resistant to empirical treatments such as 5-aminosalicylic acid, immunomodulators and steroids and often causes a perforation, requiring surgical resection. Therefore, intestinal lesions are considered to be a poor prognostic factor in Beh{\cc}et's disease. Recently, several reports have demonstrated the efficacy of anti-TNFα monoclonal antibodies, such as infliximab, against intestinal Beh{\cc}et's disease, however, it remains unknown whether anti- TNFα therapy can improve the prognosis of patients with intestinal Beh{\cc}et's disease. We herein report the case of an adult female patient with intestinal Beh{\cc}et's disease who responded well to the induction therapy with infliximab, and has been maintained in remission by scheduled administration of infliximab. Her C- reactive protein level has been sustained at a negative level, and endoscopic findings revealed complete mucosal healing. Therefore, infliximab may have the potential to induce {"}sustained deep remission{"} in patients with intestinal Beh{\cc}et's disease.",
keywords = "Infliximab, Intestinal Beh{\cc}et's disease, Mucosal healing, Sustained deep remission",
author = "Yuriko Maruyama and Tadakazu Hisamatsu and Katsuyoshi Matsuoka and Makoto Naganuma and Nagamu Inoue and Haruhiko Ogata and Yasushi Iwao and Takanori Kanai and Toshifumi Hibi",
year = "2012",
doi = "10.2169/internalmedicine.51.8005",
language = "English",
volume = "51",
pages = "2125--2129",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "16",

}

TY - JOUR

T1 - A case of intestinal Behçet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years

AU - Maruyama, Yuriko

AU - Hisamatsu, Tadakazu

AU - Matsuoka, Katsuyoshi

AU - Naganuma, Makoto

AU - Inoue, Nagamu

AU - Ogata, Haruhiko

AU - Iwao, Yasushi

AU - Kanai, Takanori

AU - Hibi, Toshifumi

PY - 2012

Y1 - 2012

N2 - Behçet's disease is a chronic relapsing disease with multiple organ system involvement, including the gastrointestinal tract, which is known as intestinal Behçet's disease. Intestinal Behçet's disease is often resistant to empirical treatments such as 5-aminosalicylic acid, immunomodulators and steroids and often causes a perforation, requiring surgical resection. Therefore, intestinal lesions are considered to be a poor prognostic factor in Behçet's disease. Recently, several reports have demonstrated the efficacy of anti-TNFα monoclonal antibodies, such as infliximab, against intestinal Behçet's disease, however, it remains unknown whether anti- TNFα therapy can improve the prognosis of patients with intestinal Behçet's disease. We herein report the case of an adult female patient with intestinal Behçet's disease who responded well to the induction therapy with infliximab, and has been maintained in remission by scheduled administration of infliximab. Her C- reactive protein level has been sustained at a negative level, and endoscopic findings revealed complete mucosal healing. Therefore, infliximab may have the potential to induce "sustained deep remission" in patients with intestinal Behçet's disease.

AB - Behçet's disease is a chronic relapsing disease with multiple organ system involvement, including the gastrointestinal tract, which is known as intestinal Behçet's disease. Intestinal Behçet's disease is often resistant to empirical treatments such as 5-aminosalicylic acid, immunomodulators and steroids and often causes a perforation, requiring surgical resection. Therefore, intestinal lesions are considered to be a poor prognostic factor in Behçet's disease. Recently, several reports have demonstrated the efficacy of anti-TNFα monoclonal antibodies, such as infliximab, against intestinal Behçet's disease, however, it remains unknown whether anti- TNFα therapy can improve the prognosis of patients with intestinal Behçet's disease. We herein report the case of an adult female patient with intestinal Behçet's disease who responded well to the induction therapy with infliximab, and has been maintained in remission by scheduled administration of infliximab. Her C- reactive protein level has been sustained at a negative level, and endoscopic findings revealed complete mucosal healing. Therefore, infliximab may have the potential to induce "sustained deep remission" in patients with intestinal Behçet's disease.

KW - Infliximab

KW - Intestinal Behçet's disease

KW - Mucosal healing

KW - Sustained deep remission

UR - http://www.scopus.com/inward/record.url?scp=84865138138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865138138&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.51.8005

DO - 10.2169/internalmedicine.51.8005

M3 - Article

VL - 51

SP - 2125

EP - 2129

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 16

ER -